سعر مارفيلون 0.15/0.03مجم 21 قرص 2022

Combined oral contraceptive: Desogestrel 0.15 mg / ethinylestradiol 0.03 mg tablets, pack of 21 tablets.

• Oral contraception.Population: Women of reproductive ageelectronic medicines compendium (emc), UK

• Common adverse reactions (1% or more): headache, nausea, abdominal pain, breast pain/tenderness, depressed or altered mood and weight increase; venous and arterial thromboembolism are rare but serious.International label, same formulation · electronic medicines compendium (emc), UK

• Presence or risk of venous thromboembolism (current or past VTE such as DVT or PE, hereditary or acquired predisposition, major surgery with prolonged immobilisation, or multiple risk factors).International label, same formulation · electronic medicines compendium (emc), UK
• Presence or risk of arterial thromboembolism (current or past myocardial infarction, angina, stroke or TIA, hereditary or acquired predisposition, migraine with focal neurological symptoms, diabetes with vascular symptoms, severe hypertension, severe dyslipoproteinaemia).International label, same formulation · electronic medicines compendium (emc), UK
• Presence or history of severe hepatic disease while liver function values have not returned to normal; presence or history of liver tumours.International label, same formulation · electronic medicines compendium (emc), UK

• Any CHC increases the risk of venous thromboembolism compared with non-use; desogestrel-containing products such as Marvelon may have up to twice the VTE risk of levonorgestrel-containing products (an estimated 9-12 per 10,000 women per year versus about 6), with the highest risk in the first year of use.International label, same formulation · electronic medicines compendium (emc), UK
• An increased risk of arterial thromboembolism (myocardial infarction, stroke) is associated with CHC use; risk factors include smoking (especially over 35 years), hypertension, obesity and age.International label, same formulation · electronic medicines compendium (emc), UK
• A meta-analysis reported a slightly increased relative risk (RR 1.24) of breast cancer diagnosis in current COC users, returning gradually to baseline within 10 years after stopping.International label, same formulation · electronic medicines compendium (emc), UK

• Hepatic enzyme inducers (e.g. phenytoin, carbamazepine, barbiturates, primidone, rifampicin, St John's wort)Increased clearance of sex hormones may cause breakthrough bleeding and contraceptive failure; use a barrier method during the inducer and for 28 days after stopping it.electronic medicines compendium (emc), UK
• Ombitasvir/paritaprevir/ritonavir and dasabuvir; glecaprevir/pibrentasvirRisk of ALT elevations; contraindicated; switch to an alternative contraceptive method before starting and restart about 2 weeks after completing the regimen.electronic medicines compendium (emc), UK
• Strong or moderate CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, clarithromycin, fluconazole, diltiazem, erythromycin)May increase plasma concentrations of the estrogen and/or progestogen.electronic medicines compendium (emc), UK

• Not indicated during pregnancy; if pregnancy occurs during use, stop further intake. Epidemiological studies have shown neither an increased risk of birth defects in children of women who used CHCs before pregnancy nor a teratogenic effect when taken inadvertently during early pregnancy.International label, same formulation · electronic medicines compendium (emc), UK
• Combined oral contraceptives may reduce the quantity and change the composition of breast milk; their use is generally not recommended until the mother has completely weaned her child. Small amounts of the steroids and/or metabolites may pass into milk.International label, same formulation · electronic medicines compendium (emc), UK

English text not available for this section.